Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamson V Moore

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Melanoma Research|March 10, 2018
Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanomaKendra C Foley, Michael I Nishimura, Tamson V Moore
Cancer Immunology, Immunotherapy : CII|October 7, 2008
Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccinationSimon Voelkl, Tamson V Moore, Michael Rehli, et al.
Molecular Immunology|January 12, 2023
NKG2D signaling shifts the balance of CD8 T cells from single cytokine- to polycytokine-producing effector cellsFrederick J Kohlhapp, Jeremy A O'Sullivan, Tamson V Moore, et al.
Scientific Reports|June 26, 2021
Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo responseSiao-Yi Wang, Tamson V Moore, Annika V Dalheim, et al.
American Journal of Respiratory Cell and Molecular Biology|March 23, 2011
Inducible costimulator controls migration of T cells to the lungs via down-regulation of CCR7 and CD62LTamson V Moore, Bryan S Clay, Judy L Cannon, et al.
Cancer Letters|May 25, 2005
A new murine tumor model for studying HLA-A2-restricted anti-tumor immunityBarbara L F Kaplan, Tamson V Moore, Karin Schreiber, et al.
Cancer Treatment and Research|October 11, 2005
Antigen recognition and T-cell biologyMichael I Nishimura, Jeffrey J Roszkowski, Tamson V Moore, et al.
Cancer Immunology, Immunotherapy : CII|June 18, 2011
Priming with very low-affinity peptide ligands gives rise to CD8(+) T-cell effectors with enhanced function but with greater susceptibility to transforming growth factor (TGF)β-mediated suppressionJeremy A O'Sullivan, Andrew Zloza, Frederick J Kohlhapp, et al.
Plos One|November 6, 2009
Inducible costimulator expression regulates the magnitude of Th2-mediated airway inflammation by regulating the number of Th2 cellsBryan S Clay, Rebecca A Shilling, Hozefa S Bandukwala, et al.
Cancer Immunology, Immunotherapy : CII|October 7, 2008
Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognitionTamson V Moore, Gretchen E Lyons, Natasha Brasic, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Melanoma Research|March 10, 2018
Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanomaKendra C Foley, Michael I Nishimura, Tamson V Moore
Cancer Immunology, Immunotherapy : CII|October 7, 2008
Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccinationSimon Voelkl, Tamson V Moore, Michael Rehli, et al.
Molecular Immunology|January 12, 2023
NKG2D signaling shifts the balance of CD8 T cells from single cytokine- to polycytokine-producing effector cellsFrederick J Kohlhapp, Jeremy A O'Sullivan, Tamson V Moore, et al.
Scientific Reports|June 26, 2021
Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo responseSiao-Yi Wang, Tamson V Moore, Annika V Dalheim, et al.
American Journal of Respiratory Cell and Molecular Biology|March 23, 2011
Inducible costimulator controls migration of T cells to the lungs via down-regulation of CCR7 and CD62LTamson V Moore, Bryan S Clay, Judy L Cannon, et al.
Cancer Letters|May 25, 2005
A new murine tumor model for studying HLA-A2-restricted anti-tumor immunityBarbara L F Kaplan, Tamson V Moore, Karin Schreiber, et al.
Cancer Treatment and Research|October 11, 2005
Antigen recognition and T-cell biologyMichael I Nishimura, Jeffrey J Roszkowski, Tamson V Moore, et al.
Cancer Immunology, Immunotherapy : CII|June 18, 2011
Priming with very low-affinity peptide ligands gives rise to CD8(+) T-cell effectors with enhanced function but with greater susceptibility to transforming growth factor (TGF)β-mediated suppressionJeremy A O'Sullivan, Andrew Zloza, Frederick J Kohlhapp, et al.
Plos One|November 6, 2009
Inducible costimulator expression regulates the magnitude of Th2-mediated airway inflammation by regulating the number of Th2 cellsBryan S Clay, Rebecca A Shilling, Hozefa S Bandukwala, et al.
Cancer Immunology, Immunotherapy : CII|October 7, 2008
Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognitionTamson V Moore, Gretchen E Lyons, Natasha Brasic, et al.
Pageof 3